Inclusion Criteria:

- Male or female patients 18 years or older

- Histologically or cytologically confirmed metastatic and/or advanced solid tumors or
lymphomas

- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

- Expected survival longer than 3 months from enrollment in the study

- Female patients who are post menopausal, surgically sterile, or agree to practice 2
effective methods of contraception or agree to abstain from heterosexual intercourse

- Male patients who agree to practice effective barrier contraception or agree to
abstain from heterosexual intercourse

Exclusion Criteria:

- Treatment with any anticancer therapy or any investigational agents within 4 weeks
before the first dose of alisertib

- Known hypersensitivity or intolerance to rifampin (for patients considered for
the rifampin DDI group) or to esomeprazole (for patients considered for the
esomeprazole DDI group)

- Recurrent nausea and/or vomiting within 14 days before the first dose of alisertib,
and known GI abnormality or GI procedure that could interfere with or modify the oral
absorption or tolerance of alisertib

- Patients requiring treatment with clinically significant enzyme inducers within 14
days before the first dose of alisertib and/or requiring the use of these medications
during the study

- A medical condition requiring use of pancreatic enzymes; or daily, chronic, or
regular use of proton pump inhibitors (PPI); or histamine (H2) receptor antagonists

- Patients requiring systemic anticoagulation (excluding low-dose aspirin, or low-dose
anticoagulation to maintain patency of venous access devices).

- Any cardiovascular condition

- Female patients who are lactating or have a positive serum pregnancy test

- Major surgery within the 14 days preceding the first dose of alisertib

- Life-threatening or uncontrolled medical illness unrelated to cancer

- Newly diagnosed or uncontrolled cancer-related central nervous system (CNS) disease

- Autologous stem cell transplant within 3 months

- Prior allogeneic bone marrow or other organ transplantation

- Other severe acute or chronic medical or psychiatric condition

- Known or suspected human immunodeficiency virus (HIV) positive or hepatitis B surface
antigen-positive status, or known or suspected active hepatitis C infection

Please note there are additional inclusion and exclusion criteria. The study center will
determine if you meet all of the criteria.